Press Releases

Sign up for Email Alerts Press Release RSS

10/22/2018
Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Term:Corporate/Financial News
Language:English
10/20/2018
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer
Term:Corporate/Financial News
Language:English
10/19/2018
Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ≥10 mut/Mb
Term:Corporate/Financial News
Language:English
10/17/2018
Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Term:$BMY
Language:English
10/12/2018
Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer
Term:Corporate/Financial News
Language:English
10/11/2018
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Term:R&D News
Language:English
09/18/2018
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Term:Corporate/Financial News
Language:English
09/14/2018
Bristol-Myers Squibb Statement on Resignation of Dr. José Baselga
Term:Corporate/Financial News
Language:English
09/12/2018
Bristol-Myers Squibb Announces Dividend
Term:Bristol-Myers
Language:English
09/12/2018
Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
Term:Opdivo
Language:English

Business Wire NewsHQ^sm